Reclast (Zoledronic Acid) Cost in New York: 2026 Pricing, Insurance & Savings

What Does Reclast (Zoledronic Acid) Actually Cost in New York?

The sticker price and the price you pay are rarely the same number. Novartis lists Reclast 5 mg at approximately $1,500 per infusion, but generic zoledronic acid (available since 2013) has pushed average cash-pay costs across New York retail and specialty pharmacies to between $300 and $600 per annual dose in 2026.

Because zoledronic acid is administered as an intravenous infusion, the total out-of-pocket figure includes both the drug cost and the facility or administration fee. A hospital outpatient infusion center in Manhattan may charge $200 to $500 for the infusion service alone, while a freestanding infusion suite or physician office in Albany or Buffalo often bills $100 to $250 for the same service. The drug itself carries Healthcare Common Procedure Coding System (HCPCS) code J3489, which most insurers recognize as a medical benefit rather than a pharmacy benefit [1].

Price variation across the state is significant. A 2024 analysis of Medicare Part B claims found that per-beneficiary spending on physician-administered osteoporosis drugs varied by more than 40% across hospital referral regions within New York State alone [2]. Patients in New York City metro-area facilities tend to pay higher facility fees than those in upstate or suburban settings.

For uninsured patients, requesting the generic formulation and choosing an independent infusion center over a hospital outpatient department is the single most effective cost-reduction strategy. Some patients report total out-of-pocket costs below $400 when combining a GoodRx or RxAssist coupon with an independent infusion site.

New York Medicaid Coverage for Zoledronic Acid

New York Medicaid covers Reclast and generic zoledronic acid for the treatment of osteoporosis, but requires prior authorization. The New York State Department of Health Medicaid Drug Utilization Review Board classifies bisphosphonates as preferred agents for postmenopausal osteoporosis when certain clinical criteria are met [3].

To secure PA approval, prescribers typically must document a DXA scan showing a T-score of −2.5 or lower at the lumbar spine, femoral neck, or total hip, or a history of fragility fracture. The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis recommends bisphosphonate therapy as first-line treatment for patients at high fracture risk [4]. New York Medicaid aligns with this recommendation.

Managed Medicaid plans in New York (such as Healthfirst, Fidelis Care, and Molina Healthcare of New York) may apply additional step-therapy requirements. Some plans require documentation that oral bisphosphonates (alendronate or risedronate) were tried and either failed or were not tolerated before approving IV zoledronic acid. Processing times for PA requests range from 24 hours to 14 business days depending on the plan, though urgent requests for patients with recent fractures are often expedited.

Medicaid enrollees pay $0 in copays for zoledronic acid once authorization is granted, as New York's Medicaid program does not impose cost-sharing for prescription drugs classified as medical benefits.

How Insurance Plans Handle Reclast in New York

Most commercial insurance plans in New York cover zoledronic acid, but how they cover it varies. The drug is almost always billed as a medical benefit (not a pharmacy benefit) because it requires in-office or infusion-center administration [5].

Commercial PPO and HMO plans. UnitedHealthcare, Aetna, Cigna, and Empire BlueCross BlueShield all include zoledronic acid on their New York formularies. Patients with these plans typically owe a specialist visit copay ($30 to $75) plus a percentage coinsurance on the drug (commonly 20% after deductible). For a patient whose plan covers 80% of the generic drug cost of $400, the drug portion of their bill would be roughly $80, plus the copay.

Medicare Part B. Zoledronic acid is covered under Medicare Part B as a physician-administered injectable. After the Part B deductible ($257 in 2026), Medicare pays 80% of the approved amount. The remaining 20% coinsurance applies, though Medigap plans or Medicare Advantage supplemental benefits often reduce this to $0 [6]. The HORIZON Key Fracture Trial (HORIZON-PFT), which enrolled 7,765 postmenopausal women and demonstrated a 70% reduction in vertebral fractures with annual zoledronic acid 5 mg over three years, provided the efficacy data that underpins Medicare's coverage determination [7].

Medicare Advantage. Plans offered by Humana, Wellcare, and others in New York may apply different prior authorization rules than original Medicare. Check with the specific plan's medical policy bulletin before scheduling the infusion.

State employee plans. The New York State Health Insurance Program (NYSHIP) covers zoledronic acid under the Empire Plan's medical benefit, subject to standard cost-sharing.

Generic Zoledronic Acid vs. Brand Reclast: The Price Gap

Generic zoledronic acid became available in the U.S. in 2013 after Novartis's patent expired. Multiple manufacturers (including Mylan, Hospira/Pfizer, and Fresenius Kabi) now produce FDA-approved generic versions of the 5 mg/100 mL intravenous solution.

The cost difference is substantial. While brand Reclast lists at approximately $1,500 per infusion, generic versions are acquired by infusion centers for $150 to $350 wholesale. This acquisition cost drives the lower cash-pay prices patients see at independent infusion sites. A February 2023 study in the Journal of Bone and Mineral Research found that generic bisphosphonate availability was associated with a 37% increase in treatment initiation among Medicare beneficiaries, suggesting that cost has been a genuine barrier to osteoporosis treatment [8].

There is no clinically meaningful difference in efficacy or safety between brand Reclast and its generic equivalents. The FDA requires generic zoledronic acid to demonstrate bioequivalence to the reference product, meaning the same active ingredient at the same dose produces the same blood levels [9]. Ask your prescriber or infusion center to specify generic zoledronic acid on the order to capture the lower price.

Dr. Ethel Siris, former director of the Toni Stabile Osteoporosis Center at Columbia University Medical Center, has stated: "The availability of generic zoledronic acid has made once-yearly IV therapy one of the most cost-effective osteoporosis treatments we have, particularly for patients who struggle with oral bisphosphonate adherence."

Compounded Zoledronic Acid in New York: What's Legal

503A compounding pharmacies in New York can compound zoledronic acid preparations under specific conditions. The New York State Board of Pharmacy permits patient-specific compounding when a licensed prescriber determines that a commercially available product does not meet a patient's medical needs (such as an allergy to an inactive ingredient in the commercial formulation) [10].

New York enforces strict oversight of 503A operations. Compounding pharmacies must hold a valid New York State license, comply with USP <797> sterile compounding standards, and compound only in response to individual patient prescriptions. Bulk compounding or anticipatory compounding without patient-specific prescriptions falls under 503B outsourcing facility rules and requires FDA registration [11].

The practical reality: because multiple FDA-approved generic zoledronic acid products are commercially available, most 503A pharmacies in New York will compound zoledronic acid only when a prescriber documents a specific clinical reason the commercial product is unsuitable. Patients should not expect compounded zoledronic acid to be cheaper than the generic; the cost of sterile compounding under USP <797> conditions often exceeds the wholesale price of the manufactured generic.

Discount Programs and Savings Cards That Work in New York

Several programs can reduce out-of-pocket costs for zoledronic acid in New York. Not all are available to every patient.

Novartis Patient Assistance Program. Novartis offers the Reclast Patient Assistance Program for uninsured or underinsured patients with household incomes below 500% of the federal poverty level. Eligible patients receive brand Reclast at no cost. Applications require documentation of income and insurance status [12].

Manufacturer co-pay cards. Novartis periodically offers co-pay assistance cards for commercially insured patients. These cards can reduce out-of-pocket costs to as low as $0 per infusion, but they are not valid for patients enrolled in Medicare, Medicaid, TRICARE, or other government-funded programs. New York's anti-copay-accumulator law (effective 2025) requires that co-pay card payments count toward a patient's deductible and out-of-pocket maximum for many plan types, which increases the long-term value of these cards for New York residents [13].

GoodRx, RxSaver, and similar platforms. These aggregators show cash prices for generic zoledronic acid at infusion centers and specialty pharmacies across New York. Prices displayed typically reflect the drug cost only, not the administration fee.

Hospital financial assistance. New York State law (Public Health Law § 2807-k) requires hospitals to offer financial assistance to patients with incomes below 300% of the federal poverty level. Patients receiving their infusion at a New York hospital outpatient department should ask the billing office about charity care eligibility before the appointment.

NeedyMeds and RxAssist. These nonprofit databases aggregate manufacturer programs, state programs, and foundation grants. The NeedyMeds zoledronic acid page lists current assistance options by state.

According to the American Association of Clinical Endocrinology (AACE), "Cost should not be a barrier to initiating osteoporosis pharmacotherapy. Clinicians should actively assist patients in identifying financial assistance programs, particularly for injectable agents where out-of-pocket costs can deter treatment adherence" [14].

Telehealth Prescribing of Zoledronic Acid in New York

New York permits telehealth evaluation and prescribing for zoledronic acid. A prescriber licensed in New York State can conduct the clinical assessment, review DXA results and laboratory work, and write the prescription via a synchronous audio-video visit [15].

The infusion itself still requires an in-person visit. Patients must present to a licensed infusion center, physician office, or hospital outpatient facility for the 15-minute IV administration. Pre-infusion labs (serum calcium, creatinine, and estimated GFR) can be ordered during the telehealth visit and completed at a local lab before the infusion date.

New York's telehealth parity law requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for the same service. This means the evaluation visit that leads to a zoledronic acid prescription should not cost more when conducted via telehealth than in person [16]. Medicare also covers telehealth evaluations for osteoporosis management under current CMS guidelines extended through 2026.

This pathway is particularly useful for patients in rural upstate New York counties where endocrinologists or osteoporosis specialists may be more than an hour's drive away. A telehealth evaluation followed by an infusion at the nearest qualified facility reduces both travel burden and total visit cost.

How to Pay the Least for Zoledronic Acid in New York

The lowest-cost pathway depends on your insurance status. Here is a decision framework based on common scenarios.

If you have commercial insurance: Confirm that your plan covers zoledronic acid as a medical benefit. Ask your prescriber to use the generic. Apply any available Novartis co-pay card. Choose an in-network freestanding infusion center over a hospital outpatient department when possible. Expected cost: $0 to $150 per annual infusion.

If you have Medicare Part B: The drug and infusion are covered after your annual deductible. If you have a Medigap supplement (Plan F or Plan G), your coinsurance is likely $0. Without a supplement, expect to pay roughly $50 to $200 for the 20% coinsurance on the combined drug-plus-administration charge.

If you have New York Medicaid: Once prior authorization is approved, your cost is $0. Ask your prescriber's office to submit the PA request with DXA results and fracture history included.

If you are uninsured: Apply to the Novartis Patient Assistance Program if your income qualifies. If not, request generic zoledronic acid, call three to five infusion centers for price quotes (emphasizing that you are self-pay), and present a GoodRx coupon. Target total cost: $300 to $600 for drug plus administration.

The HORIZON Recurrent Fracture Trial demonstrated that a single 5 mg IV dose of zoledronic acid given within 90 days of hip fracture repair reduced the risk of new clinical fractures by 35% and all-cause mortality by 28% over a median follow-up of 1.9 years [17]. At any of the price points above, one infusion per year represents a high-value intervention for patients with established osteoporosis or prior fragility fracture.